| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
ARTICLE |
Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis
Affiliations of authors: Department of Internal Medicine I, University of Cologne, Cologne, Germany (JB, SL, AE); Institute of Medical Biometry and Medical Informatics, University of Freiburg, Freiburg, Germany (GS); Technology Evaluation Center, Blue Cross and Blue Shield Association, Chicago, IL (JS, MP); Department of Veterans Affairs Chicago Healthcare System, Lakeside Division and Northwestern University, Chicago, IL (CB)
Correspondence to: Andreas Engert, MD, Department of Internal Medicine I, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany (e-mail: a.engert{at}uni-koeln.de).
Background: Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant diseases. Methods: We conducted a systematic literature review to assess the efficacy of erythropoietin to prevent or treat anemia in cancer patients with regard to red blood cell transfusions, hematologic response, adverse events, and overall survival. We searched the Cochrane Library, Medline, EMBASE, and other databases for relevant articles published from January 1985 to December 2001. We included all randomized controlled trials that compared the use of recombinant human erythropoietin (plus transfusion, if needed) with no erythropoietin treatment (plus transfusion, if needed). Relative risks (RRs) and 95% confidence intervals (CIs) were calculated under a fixed-effects model. Clinical and statistical heterogeneity were examined with sensitivity analyses and meta-regression. Statistical tests for effect estimates were two-sided. Results: We identified 27 trials involving 3287 adult patients. Patients treated with erythropoietin had a lower relative risk of having a blood transfusion than untreated patients (RR = 0.67, 95% CI = 0.62 to 0.73). Erythropoietin-treated patients with baseline hemoglobin levels lower than 10 g/dL were more likely to have a hematologic response than untreated patients (RR = 3.60, 95% CI = 3.07 to 4.23). The relative risk for thromboembolic complications after erythropoietin treatment was not statistically significantly increased (RR = 1.58, 95% CI = 0.94 to 2.66) compared with that of untreated patients. There is suggestive but inconclusive evidence that erythropoietin may improve overall survival (adjusted data: hazard ratio [HR] = 0.81, 95% CI = 0.67 to 0.99; unadjusted data: HR = 0.84, 95% CI = 0.69 to 1.02). Conclusions: Erythropoietin treatment may reduce the risk for blood transfusions and improve hematologic response in cancer patients. However, our favorable survival outcome is in contrast to two large (N = 351 and 939) recently published randomized controlled trials in which erythropoietin-treated patients had statistically significantly worse survival than untreated patients. Possible reasons for the disparity with our results include differences in study population and design, higher target hemoglobin levels and higher risk of thromboembolic complications, and concerns that erythropoietin may stimulate tumor growth.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Study Examines Effectiveness of Anti-Anemia Drug in Treatment of Cancer Patients
- Sarah L. Zielinski
J Natl Cancer Inst 2005 97: 467.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  G. Paragh, S. M. Kumar, Z. Rakosy, S.-C. Choi, X. Xu, and G. Acs RNA Interference-Mediated Inhibition of Erythropoietin Receptor Expression Suppresses Tumor Growth and Invasiveness in A2780 Human Ovarian Carcinoma Cells Am. J. Pathol., April 1, 2009; 174(4): 1504 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. May and F. R. Khuri Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion Cancer Res., June 1, 2008; 68(11): 4013 - 4017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Bennett, S. M. Silver, B. Djulbegovic, A. T. Samaras, C. A. Blau, K. J. Gleason, S. E. Barnato, K. M. Elverman, D. M. Courtney, J. M. McKoy, et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia JAMA, February 27, 2008; 299(8): 914 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aapro, R. C. Leonard, A. Barnadas, M. Marangolo, M. Untch, N. Malamos, J. Mayordomo, D. Reichert, J. L. Pedrini, L. Ukarma, et al. Effect of Once-Weekly Epoetin Beta on Survival in Patients With Metastatic Breast Cancer Receiving Anthracycline- and/or Taxane-Based Chemotherapy: Results of the Breast Cancer--Anemia and the Value of Erythropoietin (BRAVE) Study J. Clin. Oncol., February 1, 2008; 26(4): 592 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. May and F. R. Khuri Role of Erythropoietin-stimulating Agents in the Outcomes of Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 140 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tefferi Pharmaceutical Erythropoietin Use in Patients With Cancer: Is It Time to Abandon Ship or Just Drop Anchor? Mayo Clin. Proc., November 1, 2007; 82(11): 1316 - 1318. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P Steensma Erythropoiesis stimulating agents BMJ, March 31, 2007; 334(7595): 648 - 649. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Wright, Y. C. Ung, J. A. Julian, K. I. Pritchard, T. J. Whelan, C. Smith, B. Szechtman, W. Roa, L. Mulroy, L. Rudinskas, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non-Small-Cell Lung Cancer With Disease-Related Anemia J. Clin. Oncol., March 20, 2007; 25(9): 1027 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Crawford Erythropoietin: High Profile, High Scrutiny J. Clin. Oncol., March 20, 2007; 25(9): 1021 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Leo, L.-C. Horn, C. Rauscher, B. Hentschel, A. Liebmann, G. Hildebrandt, and M. Hockel Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis Clin. Cancer Res., December 1, 2006; 12(23): 6894 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Morishima, M. Ogura, S. Yoneda, H. Sakai, K. Tobinai, Y. Nishiwaki, H. Minami, T. Hotta, K. Ezaki, Y. Ohe, et al. Once-Weekly Epoetin-Beta Improves Hemoglobin Levels in Cancer Patients with Chemotherapy-Induced Anemia: A Randomized, Double-Blind, Dose-Finding Study Jpn. J. Clin. Oncol., October 1, 2006; 36(10): 655 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Canon, J. Vansteenkiste, G. Bodoky, M. V. Mateos, L. Bastit, I. Ferreira, G. Rossi, and R. G. Amado Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, February 15, 2006; 98(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hardee, Z. N. Rabbani, M. O. Arcasoy, J. P. Kirkpatrick, Z. Vujaskovic, M. W. Dewhirst, and K. L. Blackwell Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol. Cancer Ther., February 1, 2006; 5(2): 356 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist, February 1, 2006; 11(2): 206 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Quirt, M. Kovacs, F. Couture, A. R. Turner, M. Noble, R. Burkes, S. Dolan, R. K. Plante, C. Y. Lau, J. Chang, et al. Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience Oncologist, January 1, 2006; 11(1): 73 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Engert Recombinant human erythropoietin in oncology: current status and further developments Ann. Onc., October 1, 2005; 16(10): 1584 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Steensma and C. L. Loprinzi Erythropoietin Use in Cancer Patients: A Matter of Life and Death? J. Clin. Oncol., September 1, 2005; 23(25): 5865 - 5868. [Full Text] [PDF]
|
|